Boehringer Ingelheim Corporate News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Boehringer Ingelheim Social Engagements
EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements  New approach closes critical financing gap for social entrepreneurs to scale upSignificant extension of current Making More Health program, to provide financing for impact to social entrepreneurs beyond donationsContributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 11, 2021 Category: Research Source Type: news

Making-more-health-together-2021
Making More Health Together 2021:  Creating sustainable health solutions for 50 million people in vulnerable communities1,400 participants from around the world join virtual convention on November 11-12  Boehringer Ingelheim and Ashoka focus on empowerment of social entrepreneurs, celebrating a decade of partnership to tackle global healthcare issuesBy 2030, Making More Health aims to impact 50 million people in vulnerable communities, by supporting social entrepreneurs and creating smart, sustainable solutions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 11, 2021 Category: Research Source Type: news

emperor-preserved-kidney-subanalysis
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease statusIn a new sub-analysis of the landmark EMPEROR-Preserved ®Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 Empagliflozin consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m21 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2021 Category: Research Source Type: news

commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovationBoehringer Ingelheim marks One Health Day 2021 by evolving commitments to sustainable development relating to the company ’s employees, partners and wider communitiesUpdates include expanding healthcare access for non-communicable diseases for 50 million people in vulnerable communities, and an additional 50 million people reached through engagement and social entrepreneurship (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 3, 2021 Category: Research Source Type: news

environmental sustainability commitments
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments  Boehringer Ingelheim marks COP26 by announcing updates to its strategic approach to sustainable development  The company commits to becoming carbon ne utral in company operations by 2030 and further reducing the overall water footprint, operational waste to landfill and resource useBoehringer Ingelheim implements ambitious internal carbon price of EUR 100 per ton CO2 emissions to foster low carbon technologies and solutionsThe company invests EUR 130 million to implement strategic green projects contributing to environmental commitments (S...
Source: Boehringer Ingelheim Corporate News - October 31, 2021 Category: Research Source Type: news

EMA filing acceptance and validation for spesolimab
Boehringer Ingelheim announces European Medicines Agency ’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 28, 2021 Category: Research Source Type: news

collaboration-kings-college-london
Boehringer Ingelheim and King ’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophreniaThe collaboration will produce a comprehensive clinical research program in major depressive disorder and schizophrenia, building upon Boehringer Ingelheim ’s circuitry-based approach to precision psychiatry and further solidifies commitment to provide better treatments for people living with serious mental health conditions.Together, Boehringer Ingelheim and King ’s College London aim to identify more patient-specific biomarkers, improving the development of therapies for cog...
Source: Boehringer Ingelheim Corporate News - October 27, 2021 Category: Research Source Type: news

opening-solids-launch-fabrik
Boehringer Ingelheim opens high-tech tablet production facility in IngelheimTotal investment of EUR 90 million   Smart factory will further speed the market launch of innovative drugsBoosts pharmaceutical production in Germany and Europe (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 27, 2021 Category: Research Source Type: news

Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders  Boehringer Ingelheim will be commencing a new collaboration with Thoeris GmbH with the goal of advancing a first-in-class approach for the treatment of urea cycle disorders (UCDs) independent of the underlying monogenetic causeUCDs are genetic disorders with highly variable onset and severity, causing excess ammonia levels in the blood, which can lead to irreversible brain damage, coma and deathThis collaboration is part of Boehringer Ingelheim ’s commitment to leveraging emerging science to deliver transformative t...
Source: Boehringer Ingelheim Corporate News - October 26, 2021 Category: Research Source Type: news

BI increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030Boehringer Ingelheim marks the World Health Summit 2021 by announcing updates to its strategic approach to sustainable developmentThe company commits to investing EUR 250 million in collaborations to combat infectious diseases in humans and animals, and increases investment in health innovation and research to tackle non-communicable diseases worldwide  In addition, Boehringer Ingelheim commits to expanding he...
Source: Boehringer Ingelheim Corporate News - October 25, 2021 Category: Research Source Type: news

Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic FibrosisBoehringer Ingelheim has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology   Partners aim to expedite the development of the novel, inhaled cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy BI 3720931 as a long-lasting therapeutic option for patients with cystic fibrosis (CF) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 18, 2021 Category: Research Source Type: news

university-of-medical-excellence-harvard
Boehringer Ingelheim Launches University of Medicine ExcellenceInaugural ’Accelerate’ program designed and delivered by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairsThe University of Medicine Excellence will help Boehringer Ingelheim to accelerate progress in turning patient-focused innovation into life-changing treatmentsHarvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairsInvestment of 3.4 million USD until end of next year (Sour...
Source: Boehringer Ingelheim Corporate News - October 11, 2021 Category: Research Source Type: news

additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 8, 2021 Category: Research Source Type: news

inauguration_biopharmaceutical_production_facility_vienna
Boehringer Ingelheim inaugurates biopharmaceutical production facility in Vienna, AustriaAdds 185,000 litres of biopharmaceutical production capacityHigh degree of digitalization and automation through smart technologies and artificial intelligence applicationsMulti-product setup enables production of a large variety of molecule formatsInvestment of more than 700 million EUR, creating 500 new jobs (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 5, 2021 Category: Research Source Type: news

Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce strategic collaboration to advance monoclonal antibody biotherapeutics in animal healthBoehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary medicinesStrengthening partnership efforts to accelerate innovation and growth is one of the key elements of Boehringer Ingelheim ’s strategy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 21, 2021 Category: Research Source Type: news